- Home
- JAZZ vs EPAM Comparison
JAZZ vs EPAM Comparison
Compare JAZZ & EPAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- EPAM
- Stock Information
- Founded
- JAZZ 2003
- EPAM 1993
- Country
- JAZZ Ireland
- EPAM United States
- Employees
- JAZZ N/A
- EPAM N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- EPAM EDP Services
- Sector
- JAZZ Health Care
- EPAM Technology
- Exchange
- JAZZ Nasdaq
- EPAM Nasdaq
- Market Cap
- JAZZ 8.2B
- EPAM 7.9B
- IPO Year
- JAZZ 2007
- EPAM 2012
- Fundamental
- Price
- JAZZ $138.54
- EPAM $154.78
- Analyst Decision
- JAZZ Strong Buy
- EPAM Buy
- Analyst Count
- JAZZ 14
- EPAM 15
- Target Price
- JAZZ $180.14
- EPAM $219.73
- AVG Volume (30 Days)
- JAZZ 670.8K
- EPAM 584.7K
- Earning Date
- JAZZ 11-05-2025
- EPAM 11-06-2025
- Dividend Yield
- JAZZ N/A
- EPAM N/A
- EPS Growth
- JAZZ N/A
- EPAM 0.62
- EPS
- JAZZ N/A
- EPAM 7.02
- Revenue
- JAZZ $4,086,695,000.00
- EPAM $5,071,013,000.00
- Revenue This Year
- JAZZ $5.70
- EPAM $16.65
- Revenue Next Year
- JAZZ $6.16
- EPAM $7.23
- P/E Ratio
- JAZZ N/A
- EPAM $22.29
- Revenue Growth
- JAZZ 4.52
- EPAM 9.73
- 52 Week Low
- JAZZ $95.49
- EPAM $138.15
- 52 Week High
- JAZZ $148.06
- EPAM $269.00
- Technical
- Relative Strength Index (RSI)
- JAZZ 62.66
- EPAM 53.35
- Support Level
- JAZZ $134.09
- EPAM $140.84
- Resistance Level
- JAZZ $139.75
- EPAM $157.49
- Average True Range (ATR)
- JAZZ 3.08
- EPAM 4.80
- MACD
- JAZZ -0.21
- EPAM 1.44
- Stochastic Oscillator
- JAZZ 83.51
- EPAM 83.73
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm that offers platform engineering, software development, and consulting services. EPAM's largest market is North America, which represents approximately 60% of revenue. Offerings span assisting companies with new technologies, such as artificial intelligence, virtual reality, and robotics.